Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.30
-4.81 (-2.29%)
AAPL  266.18
+1.60 (0.60%)
AMD  196.60
-3.55 (-1.77%)
BAC  51.07
-1.99 (-3.75%)
GOOG  311.69
-3.21 (-1.02%)
META  637.25
-18.41 (-2.81%)
MSFT  384.60
-12.63 (-3.18%)
NVDA  191.64
+1.82 (0.96%)
ORCL  141.31
-6.77 (-4.57%)
TSLA  399.83
-11.99 (-2.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.